MAPK3 and Alzheimer disease: Accordingly, in the present study, subjects AD-free at time of death show a non-significant dropping tendency (− 26%) of total ERK1/2 expression when compared to controls whereas only a 7% reduction is obtained in AD-treated (data not shown).